Overview
Collecting duct carcinoma (CDC), also known as Bellini duct carcinoma, is a rare and aggressive subtype of renal cell carcinoma that arises from the epithelial cells lining the collecting ducts of the kidney. It accounts for less than 1-2% of all renal cell carcinomas. The tumor originates in the medullary region of the kidney and tends to grow rapidly, often presenting at an advanced stage with local invasion or distant metastases. The disease primarily affects the urinary system but can metastasize to the lungs, lymph nodes, liver, bone, and adrenal glands. Key symptoms include flank pain, hematuria (blood in the urine), a palpable abdominal mass, weight loss, fatigue, and fever. Many patients present with locally advanced or metastatic disease at the time of diagnosis, which contributes to the poor prognosis associated with this tumor type. Imaging studies such as CT scans typically reveal an infiltrative renal mass centered in the medulla, and definitive diagnosis requires histopathological examination showing characteristic tubulopapillary architecture with high-grade cytology and a desmoplastic stromal reaction. The treatment landscape for collecting duct carcinoma remains challenging due to its rarity and aggressive behavior. Radical nephrectomy (surgical removal of the affected kidney) is the primary treatment for localized disease. However, CDC is generally resistant to conventional therapies used for other renal cell carcinoma subtypes, including targeted therapies such as tyrosine kinase inhibitors. Platinum-based chemotherapy regimens (similar to those used for urothelial carcinomas) have shown some activity and are often considered for metastatic disease. More recently, immune checkpoint inhibitors have been explored, though evidence remains limited. Overall prognosis is poor, with median survival for metastatic disease often reported as less than one to two years.
Also known as:
Sporadic
Usually appears on its own, not inherited from a parent
Adult
Begins in adulthood (age 18 or older)
FDA & Trial Timeline
2 eventsGiuseppe Procopio — PHASE2
Peking University Cancer Hospital & Institute — PHASE2
Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
Treatments
No FDA-approved treatments are currently listed for Collecting duct carcinoma.
2 clinical trialsare actively recruiting — trials can provide access to cutting-edge therapies.
View clinical trials →Rare Disease Specialist
Rare Disease Specialist
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to Collecting duct carcinoma.
Community
No community posts yet. Be the first to share your experience with Collecting duct carcinoma.
Start the conversation →Latest news about Collecting duct carcinoma
1 articlesCaregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Common questions about Collecting duct carcinoma
What is Collecting duct carcinoma?
Collecting duct carcinoma (CDC), also known as Bellini duct carcinoma, is a rare and aggressive subtype of renal cell carcinoma that arises from the epithelial cells lining the collecting ducts of the kidney. It accounts for less than 1-2% of all renal cell carcinomas. The tumor originates in the medullary region of the kidney and tends to grow rapidly, often presenting at an advanced stage with local invasion or distant metastases. The disease primarily affects the urinary system but can metastasize to the lungs, lymph nodes, liver, bone, and adrenal glands. Key symptoms include flank pain,
How is Collecting duct carcinoma inherited?
Collecting duct carcinoma follows a sporadic inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.
At what age does Collecting duct carcinoma typically begin?
Typical onset of Collecting duct carcinoma is adult. Age of onset can vary across affected individuals.
Are there clinical trials for Collecting duct carcinoma?
Yes — 2 recruiting clinical trials are currently listed for Collecting duct carcinoma on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.
Which specialists treat Collecting duct carcinoma?
13 specialists and care centers treating Collecting duct carcinoma are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.